Expert Opinion on Pharmacotherapy最新文献_第3页

Aprocitentan: a new horizon in the treatment of hypertension. 阿普昔坦：高血压治疗的新领域。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-28 DOI: 10.1080/14656566.2025.2552901

Eviatar Fields, Ernesto L Schiffrin

{"title":"Aprocitentan: a new horizon in the treatment of hypertension.","authors":"Eviatar Fields, Ernesto L Schiffrin","doi":"10.1080/14656566.2025.2552901","DOIUrl":"https://doi.org/10.1080/14656566.2025.2552901","url":null,"abstract":"Introduction: There has been a lack of novel medication classes approved for reducing blood pressure (BP) in hypertensive patients. Endothelins, powerful vasoconstricting peptides, have been at the forefront of experimental hypertension research since they were discovered in 1988. The recent PRECISION trial demonstrated the efficacy of aprocitentan, a novel endothelin receptor antagonist, in lowering blood pressure in patients with resistant hypertension (RH). This trial was the driving force behind the approval of aprocitentan in 2024 for the treatment of resistant hypertension.Areas covered: This clinical trial review will cover the literature leading to the approval of aprocitentan and argue for its use on top of current treatments of hypertension. We argue for the need of novel anti-hypertensive medication classes and provide a brief overview of endothelin receptor antagonists. Finally, we will describe the PRECISION trial and highlight the key benefits of aprocitentan that it elucidated.Expert opinion: The PRECISION trial demonstrated numerous key benefits of aprocitentan, including efficacy in reducing BP and proteinuria, minimal adverse side effects, and efficacy in patients with advanced chronic kidney disease (CKD) without development of hyperkalemia. However, a lack of long-term data necessitates future investigation regarding safety. Aprocitentan may represent a novel therapeutic alternative to treat patients with RH and CKD.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":"26 11-12","pages":"1263-1270"},"PeriodicalIF":2.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of dopamine agonists on cardiometabolic risk factors: a systematic review and meta-analysis. 多巴胺激动剂对心脏代谢危险因素的影响：系统回顾和荟萃分析。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-06-27 DOI: 10.1080/14656566.2025.2525363

Yizhuo Xue, Mohammad Hassan Sohouli, Nathalia Sernizon Guimarães

{"title":"The effect of dopamine agonists on cardiometabolic risk factors: a systematic review and meta-analysis.","authors":"Yizhuo Xue, Mohammad Hassan Sohouli, Nathalia Sernizon Guimarães","doi":"10.1080/14656566.2025.2525363","DOIUrl":"10.1080/14656566.2025.2525363","url":null,"abstract":"Introduction: Despite investigating the various effects of dopamine agonists (DA) on cardiometabolic-related factors, there are conflicting findings in this field. This study aimed to investigate the effect of DA on changes in various factors related to cardiometabolic diseases.Methods: Comprehensive search was performed across five databases using predefined keywords to identify randomized controlled trials investigating the impact of DA on cardiometabolic factors. The combined weighted mean difference (WMD) and 95% confidence intervals (CI) were analyzed using a random-effects model.Results: Findings from 22 studies demonstrated significant reductions in fasting blood sugar (FBS) (WMD: -16.95 mg/dl; 95% CI: -23.59, -10.31), insulin (WMD: -2.02 µU/ml; 95% CI: -3.63 to -0.40), HOMA-IR (WMD: -0.82; 95% CI: -1.51 to -0.13), and HbA1c (WMD: -0.73; 95% CI: -0.96 to -0.49) as well as Systolic (SBP) (WMD: -3.75 mg/Hg; 95% CI: -6.25, -1.25) and diastolic blood pressure (DBP) (WMD: -3.45 mg/Hg; 95% CI: -5.55, -1.36) levels following intervention with DA compared to the control group. Subgroup analyses provided additional insights, revealing that bromocriptine had a more pronounced effect on glucose metabolism markers than other DA.Conclusions: It appears that DA, along with other lifestyle factors, can lead to significant improvements in some factors associated with cardiometabolic.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1321-1331"},"PeriodicalIF":2.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selecting optimal therapy for large granular lymphocytic (LGL) leukemia: current state and future prospects based on molecularly-defined characterization. 大颗粒淋巴细胞（LGL）白血病的最佳治疗选择：基于分子定义特征的现状和未来前景

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-06-22 DOI: 10.1080/14656566.2025.2522811

Victor M Samperio, Ifeoma Ike, Constantin A Dasanu

引用次数: 0

Evaluation of the effect of SGLT-2 inhibitors on atrial fibrillation recurrence in diabetic patients. SGLT-2抑制剂对糖尿病患者房颤复发的影响。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-07-03 DOI: 10.1080/14656566.2025.2527189

Mücahit Yarar, Hasan Ari, Selma Ari, Ahmet Tütüncü, Mehmet Melek, Tahsin Bozat

{"title":"Evaluation of the effect of SGLT-2 inhibitors on atrial fibrillation recurrence in diabetic patients.","authors":"Mücahit Yarar, Hasan Ari, Selma Ari, Ahmet Tütüncü, Mehmet Melek, Tahsin Bozat","doi":"10.1080/14656566.2025.2527189","DOIUrl":"10.1080/14656566.2025.2527189","url":null,"abstract":"Background: The aim of this study was to investigate the effect of SGLT-2 (sodium glucose cotransporter-2) inhibitors on AF (atrial fibrillation) recurrence in patients diagnosed with diabetes mellitus (DM) who underwent Direct Current Cardioversion (DCCV) in our clinic.Research design and methods: Consecutive DCCV was performed to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who didn't use SGLT-2 inhibitors). The two groups (SGLT-2 inhibitor user group and control group) were monitored for AF recurrence on the first day, then at one, three, and six months after CV.Results: During the six-month follow-up period, AF recurrence developed in 24 (40%) patients in SGLT-2 inhibitor group and in 35 (58.3%) of the control group, p = 0.04. In univariable analysis, AF duration, non-use of SGLT-2 inhibitor, left atrium diameter, TAPSE value and in multivariable analysis, AF duration OR: 4.98; 95%CI (2.39-10.38), p < 0,001 and non-use of SGLT-2 inhibitors OR: 0.35; 95%CI (0.13-0.90), p = 0.03 were found to be independent predictors for AF recurrence.Conclusion: AF recurrence ratio is significantly lower in patients using SGLT-2 inhibitors, in six-month follow-up period. AF duration and SGLT-2 inhibitor non-use were independent predictors, for AF recurrence in DM patients (NCT06951737).Clinical trial registration: www.clinicaltrials.gov identifier is: NCT06951737.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1343-1349"},"PeriodicalIF":2.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing cystic fibrosis treatment: investigational agents on the horizon. 推进囊性纤维化治疗：即将问世的研究性药物。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-07-25 DOI: 10.1080/14656566.2025.2538275

Lúcia Santos, Mariana Camargo, Vito Terlizzi, Miquéias Lopes-Pacheco

{"title":"Advancing cystic fibrosis treatment: investigational agents on the horizon.","authors":"Lúcia Santos, Mariana Camargo, Vito Terlizzi, Miquéias Lopes-Pacheco","doi":"10.1080/14656566.2025.2538275","DOIUrl":"10.1080/14656566.2025.2538275","url":null,"abstract":"Introduction: Cystic fibrosis (CF) treatment has been transformed by CF transmembrane conductance regulator (CFTR) modulator therapies, yet significant gaps remain for those with non-responsive or modestly responsive (below therapeutically relevant levels) genotypes and advanced disease. Emerging agents for genetic therapies and targeting symptoms are in development and offer hope for broader, more durable clinical benefits. This review synthesizes the latest clinical advances aiming to shape the future of CF care.Areas covered: We examine investigational agents in clinical development, including: (1) alternative CFTR modulators (e.g., potentiators, correctors, and amplifiers); (2) gene-based therapies utilizing viral and non-viral vectors; (3) anti-inflammatory approaches; and (4) infection-targeted therapies. Clinical trial data and combination strategies are discussed.Expert opinion: Despite dramatic improvements in clinical outcomes and survival in people with CF on modulator drugs, further efforts are warranted for ineligible/non-responsive individuals or intolerant to modulators. In addition, it remains vital to identify novel therapeutic strategies to mitigate lung damage and disease progression as infection and inflammation persist even in people with CF receiving 'highly effective' modulator therapy.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1297-1310"},"PeriodicalIF":2.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease. 芬烯酮联合SGLT-2抑制剂：建立治疗糖尿病肾病的信心

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-25 DOI: 10.1080/14656566.2025.2547803

Panagiotis Stachteas, Athina Nasoufidou, Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias

引用次数: 0

Expert-based recommendations on acetaminophen for musculoskeletal pain: insights from the Italian MOST pain panel. 对乙酰氨基酚对肌肉骨骼疼痛的专家建议：来自意大利MOST疼痛小组的见解。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-07-01 DOI: 10.1080/14656566.2025.2523976

Massimiliano Carassiti, Alessandro Massè, Luca Miceli, Filomena Puntillo, Giuseppe Solarino, Giuseppe Teori, Patrizia Romualdi

{"title":"Expert-based recommendations on acetaminophen for musculoskeletal pain: insights from the Italian MOST pain panel.","authors":"Massimiliano Carassiti, Alessandro Massè, Luca Miceli, Filomena Puntillo, Giuseppe Solarino, Giuseppe Teori, Patrizia Romualdi","doi":"10.1080/14656566.2025.2523976","DOIUrl":"10.1080/14656566.2025.2523976","url":null,"abstract":"Introduction: Musculoskeletal (MSK) pain remains a prevalent cause of disability and healthcare burden. Acetaminophen is widely used for its safety and accessibility, but its positioning within multimodal pain strategies varies across healthcare systems.Areas covered: This expert-based position paper aims to offer practical reflections on the role of acetaminophen in managing acute MSK pain, based on the experience of a multidisciplinary panel of Italian clinicians. The manuscript addresses current prescribing practices, organizational barriers, and opportunities for optimizing acetaminophen use across clinical settings.Expert opinion: Rather than presenting a systematic review, this paper synthesizes experiential knowledge and clinical reasoning drawn from routine practice. The insights may be particularly relevant for healthcare systems undergoing reform or seeking to strengthen pain management strategies for managing acute musculoskeletal pain across all age groups.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1333-1342"},"PeriodicalIF":2.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-17 DOI: 10.1080/14656566.2025.2535773

引用次数: 0

Efficacy and safety of Mitapivat in sickle cell disease: a systematic review. 米他伐治疗镰状细胞病的疗效和安全性：一项系统综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-07 DOI: 10.1080/14656566.2025.2514504

Shalu R Chaudhary, Komal Sharma, Mahalaqua Nazli Khatib, Deepak B Saxena

{"title":"Efficacy and safety of Mitapivat in sickle cell disease: a systematic review.","authors":"Shalu R Chaudhary, Komal Sharma, Mahalaqua Nazli Khatib, Deepak B Saxena","doi":"10.1080/14656566.2025.2514504","DOIUrl":"10.1080/14656566.2025.2514504","url":null,"abstract":"Background: Sickle cell disease (SCD) is a chronic hemoglobinopathy marked by hemolytic anemia, VOEs, and multiorgan complications. Mitapivat, an oral Pyruvate Kinase (PK) activator, has emerged as a potential disease-modifying therapy. This systematic review assessed the efficacy and safety of Mitapivat in individuals with SCD.Methods: A systematic literature search was conducted from different search engines from inception. The review followed PRISMA 2020 guidelines, and the protocol was registered in PROSPERO [CRD420251000061]. RCTs and NRSIs evaluating Mitapivat monotherapy were included. ROB was assessed. A narrative synthesis was undertaken due to heterogeneity.Results: One RCT and two NRSIs involving 156 participants were included. Reduced annualized Vaso-occlusive episodes (VOE) rates compared to placebo by 51.6% (50 mg) and 70.0% (100 mg). Statistically significant hemoglobin response was observed in 46.2%-56% of participants. Increased markers of hemolysis and reduced transfusion requirements in Mitapivat groups were reported. However, SAEs were low, in 8%-19% of Mitapivat recipients.Conclusions: Preliminary evidence suggests Mitapivat demonstrates potential to reduce VOEs, improve hemoglobin levels, and decrease hemolysis with an acceptable safety profile. However, small sample sizes, lack of functional outcomes, and limited follow-up warrant cautious interpretation. Further large-scale RCTs are needed to validate these findings and establish a long-term benefit-risk balance.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1229-1236"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential of cenobamate as a broad-spectrum antiseizure medication. 辛奥巴酸作为广谱抗癫痫药物的潜力。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-11 DOI: 10.1080/14656566.2025.2517352

Susan M Melnick, Sunita N Misra, Marc Kamin, Louis Ferrari, Kelli J Glenn

{"title":"Potential of cenobamate as a broad-spectrum antiseizure medication.","authors":"Susan M Melnick, Sunita N Misra, Marc Kamin, Louis Ferrari, Kelli J Glenn","doi":"10.1080/14656566.2025.2517352","DOIUrl":"10.1080/14656566.2025.2517352","url":null,"abstract":"Introduction: The process of diagnosing patients with epilepsy and selecting the optimal drug remains a significant challenge. Broad-spectrum antiseizure medications (ASMs) treat focal and generalized seizures without worsening other seizure types, making them the drug of choice when the exact seizure classification for patients is unknown. Cenobamate, an ASM approved for the treatment of adult focal seizures, has demonstrated strong efficacy, including high rates of seizure freedom. Evidence suggests that cenobamate has potential to be a broad-spectrum ASM.Areas covered: Considerations for the selection of broad- versus narrow-spectrum ASMs are discussed and an overview of preclinical, clinical, and real-world evidence relating to cenobamate as a potential broad-spectrum ASM is presented.Expert opinion: Combined evidence from preclinical data, clinical study data, and real-world evidence may indicate that cenobamate may be a broad-spectrum ASM. Evidence is accumulating regarding the utility of cenobamate in treating primary generalized tonic-clonic (PGTC) and seizures associated with developmental epileptic encephalopathies such as Lennox-Gastaut syndrome and Dravet syndrome. Results from the ongoing cenobamate trial in patients with idiopathic generalized epilepsy will determine the efficacy of cenobamate for the treatment of PGTC seizures.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1177-1189"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0